Deep Breeze™: Novel Software Application Extends VRI(TM) Capabilities to Predicting Post-Operative Lung Function

MANNHEIM, Germany--(BUSINESS WIRE)--Deep Breeze Ltd., manufacturer of the FDA approved VRIxp™ & VRIxv™ lung imaging systems, announced that it has received CE mark for its O-Plan application extending the usefulness of Deep Breeze's revolutionary VRI™ technology to patients eligible for lung cancer resection. The application has recently received the CE mark and it is used by thoracic surgeons in European Union countries.
MORE ON THIS TOPIC